« Return to News | Awards & Advancement

Perrigo appoints Keith Webber head of regulatory review

Monday, September 23, 2013 09:46 AM

Perrigo has appointed Keith Webber head of regulatory review, effective Oct. 21. This new role will have responsibility for advancing the approval of all of Perrigo's Consumer Healthcare (CHC) and Prescription Pharmaceutical (Rx) regulatory applications pending with the FDA, providing guidance on scientific and regulatory strategy for new CHC and Rx pipeline products under development and continuously advancing the quality of new regulatory applications. 

Previously, Keith was acting director of the office of the FDA's pharmaceutical science in the Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. He also has been director of Office of Generic Drug (OGD), where he directed FDA regulation of generic pharmaceuticals including, legal, chemistry, bioequivalence, microbiology, clinical and labeling. He was in several leadership roles within the FDA responsible for regulating pharmaceutical quality, biopharmaceutical drug development and monoclonal antibody-related biopharmaceuticals research and review.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.